MKMitsuru Kaise

Mitsuru Kaise

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mitsuru Kaise has a total of 158 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A case of gastric adenocarcinoma of the fundic gland mucosa type treated by endoscopic submucosal dissection after eight-year observation

    by Nobuhiko Ogasawara, Takahito Toba, Toshiro Iizuka, Shu Hoteya, Naoko Inoshita, Mitsuru Kaise

    A 70-year-old male had undergone esophagogastroduodenoscopy (EGD) every year for evaluation of chronic gastritis since 2007. Endoscopy showed an area of discoloration with submucosal tumor-like shape, measuring 10mm on the anterior wall in the upper portion of the stomach. It exhibited dilated superficial vessels with branching architecture. Biopsy had been performed several times, but there was no evidence of malignancy. In 2015, EGD and biopsy were performed again. From pathological examination, gastric adenocarcinoma of the fundic gland type was suspected. We performed endoscopic submucosal dissection and achieved complete resection. The final pathological diagnosis was gastric adenocarcinoma of fundic gland mucosa type. The shape and diameter of the lesion had not significantly changed over the eight-year period. Here we report a rare case of gastric adenocarcinoma of the fundic gland mucosa type that showed very slow progression.


  • 1033 LONG-TERM OUTCOMES OF ENDOSCOPIC RESECTION FOR SUPERFICIAL ESOPHAGEAL ADENOCARCINOMA

    by Noboru Kawata, Seiichiro Abe, Ryu Ishihara, Ichiro Oda, Hiroaki Takahashi, Hiroyuki Ono, Junko Fujisaki, Kenichi Goda, Mitsuru Kaise, Kenro Kawada, et al.

  • Differences between gastric signet‐ring cell carcinoma and poorly differentiated adenocarcinoma: A comparison of histopathologic features determined by mucin core protein and trefoil factor family peptide immunohistochemistry

    by Ai Fujimoto, Yukio Ishikawa, Toshiharu Ishii, Akihiro Yamada, Yoshinori Igarashi, Yasukazu Ohmoto, Mitsuru Kaise

    We investigated differences between the pathological features of gastric signet‐ring cell carcinoma (sig) and poorly differentiated adenocarcinoma (por) by examining the expressions of the trefoil factor family peptides (TFFs) and mucin core proteins (MUCs). Ninety‐seven tissues of 97 gastric cancer patients were selected for this study. After gastrectomy, the major histopathologic types were determined to be sig, solid‐type poorly differentiated adenocarcinoma (por1), non‐solid type poorly differentiated adenocarcinoma (por2), and well‐differentiated tubular adenocarcinoma (tub1). We evaluated the prevalence of positive staining for MUCs (MUC5AC and MUC2) and TFFs (TFF1 and TFF3) and assessed the correlation between MUCs and TFFs in each histopathological type. The rate of MUC2 expression significantly differed between sig and por2 (50.0% vs 11.7%, P = 0.011). TFF3 expression in sig significantly differed from TFF3 expression in both por2 (100% vs 17.6%, P < 0.0001) and por1 (100% vs 33.3%, P = 0.0004). MUC5AC and TFF1 expressions were significantly correlated in por1 (r = 0.705, P = 0.002), por2 (r = 0.535, P = 0.0009), and tub1 (r = 0.470, P = 0.0034), while MUC2 and TFF3 expressions were significantly correlated only in sig (r = 0.593, P = 0.040). The expression and correlation patterns of the TFFs and MUCs suggest that the histopathologic features of gastric sig differ from those of por.


  • Clinicopathological features of superficial non-ampurally duodenal epithelial tumor; gastric phenotype of histology correlates to higher malignant potency

    by Takahito Toba, Naoko Inoshita, Mitsuru Kaise, Kosuke Nomura, Yasutaka Kuribayashi, Masami Tanaka, Satoshi Yamashita, Tsukasa Furuhata, Daisuke Kikuchi, Akira Matsui, et al.

    Background Superficial non-ampullary duodenal epithelial tumors (SNADETs) are relatively rare, but they are now being detected more frequently due to advances in endoscopic technology. Nevertheless, the pathological nature of SNADETs remains unclear and a management strategy for these tumors has not been established. Methods To elucidate the clinicopathological features, we conducted a retrospective analysis of 138 endoscopically resected SNADETs. Lesions were classified into two groups by histological grade according to the Vienna classification: category 3 (71 lesions, 51.4%) and category 4/5 (67 lesions, 48.6%). Results Compared with category 3 lesions, category 4/5 lesions were significantly more common in elderly patients (p < 0.001) and had a significantly larger tumor diameter (p = 0.001). Immunohistochemical analysis showed that category 4/5 lesions expressed MUC5AC (p = 0.002), MUC6 (p < 0.001), and p53 (p = 0.003) significantly more frequently and expressed CD10 (p = 0.002) and CDX2 (p = 0.029) significantly less frequently. Multivariate regression analysis showed that advanced age (p < 0.001), MUC6 expression (p = 0.001), and p53 expression (p = 0.004) were independent risk factors for a classification of category 4/5. In addition, advanced age (p = 0.010) and MUC5AC expression (p = 0.011) were identified as risk factors for lesions classified as category 4.2 (noninvasive carcinoma) or higher. All category 5 lesions expressed MUC5AC. Conclusions The gastric phenotype of MUC5AC and MUC6 may be linked to the malignant potential of SNADETs.


  • Multidisciplinary approach for cT1bN0 esophageal cancer.

    by Toshiro Iizuka, Daisuke Kikuchi, Shu Hoteya, Mitsuru Kaise, Harushi Udagawa

    133 Background: The standard treatment for cT1bN0 esophageal squamous cell carcinoma (ESCC) was once surgery, but endoscopic submucosal dissection (ESD) following by additional treatment (ESD+α) are now being applied. Accordingly, we examined treatment outcomes for cT1bN0 ESCC to assess the validity of these treatments in terms of diagnostic accuracy and post-treatment prognosis. Methods: A total of 174 patients with ESCC were diagnosed as cT1b by endoscopic ultrasound (EUS) and white-light imaging between January 2008 and December 2014. Twenty-six patients diagnosed as cN+ by EUS or CT/PET were excluded. The diagnostic accuracy of invasion depth and lymph node metastasis was analyzed along with the post-treatment prognosis. Results: Initial treatment was ESD for 102 patients (ESD group) and surgery for 46 patients (surgery group). The histological diagnosis was T1a in 63 patients and T1b in 85 patients, meaning that 57.4% of the patients were accurately diagnosed. In the surgery group, 30 patients (65.2%) were accurately diagnosed as cN0. In the ESD group, 80 patients had an invasion depth of T1a-MM or deeper, which has a potential risk of metastasis. Additional surgery was performed for 15 patients, additional chemotherapy or chemoradiotherapy was performed for 43 patients, and follow-up without additional treatment was for 22 patients. Recurrence during follow-up was observed in 8 patients (lymph nodes in5 patients; other organs in 3 patients). Of the 16 patients with histological lymph node metastasis in the surgery group, 10 underwent adjuvant chemotherapy. Recurrence was noted in 3 patients (lymph nodes in 1 patient; other organs in2 patients). The mean follow-up period was 39 months for the ESD group and 45.8 months for the surgery group. Three- and five-year survival rates were respectively 93.1% and 79.3% in the ESD group and 89.8% and 85.1% in the surgery group, with no significant differences between the groups. Conclusions: Accuracy of preoperative diagnosis of invasion depth is still not high, which makes the ESD+α strategy an acceptable. As mid- to long-term outcomes were favorable in both groups, it appears that favorable outcomes can be obtained by performing multidisciplinary therapy based on the histological diagnosis.

  • WEO Newsletter

    by Mitsuru Kaise, Hisao Tajiri

  • Salvage endoscopic submucosal dissection for the treatment of esophageal squamous cell carcinoma after local treatment failure with chemotherapy, radiotherapy, or chemoradiotherapy.

    by Toshiro Iizuka, Daisuke Kikuchi, Shu Hoteya, Akihiro Yamada, Mitsuru Kaise

    148 Background: Chemotherapy (CT), radiotherapy (RT), and chemoradiotherapy (CRT) are efficacious treatment options for esophageal squamous cell carcinoma (ESCC). However, local treatment failure remains a major problem. In this study, we applied endoscopic submucosal dissection (ESD) for the treatment of ESCC after local treatment failure with CT, RT, or CRT. The efficacy, safety, and feasibility of salvage ESD were assessed. Methods: Between 2008 and 2014, 611 patients underwent ESD for superficial ESCC in our hospital. Of them, 14 required salvage ESD: 7 for local treatment failure after CT, 4 after CRT, and 3 after RT. Each patient was treated with CT using 5-fluorouracil + cisplatin or RT, which consisted of >50 Gy of irradiation with or without concurrent CT. The following clinical findings were confirmed in all patients: no evidence of lymph node or distant metastasis after treatment, and an endoscopically resectable lesion. Results: The male to female ratio was 11:3 and the mean age was 64.9 (44-81) years. Clinical stages before treatment were T1b/T2/T3/T4 in 10/1/2/1, N0/1 in 7/7, and M0/1 in 13/1, respectively. The mean tumor size was 18.6 mm, and the mean procedure time was 45.7 min. En bloc resection was achieved in 100% of cases, and the R0 resection rate was 78.6%. Histopathological assessment of specimens taken at salvage ESD revealed that 6 lesions (42.9%) had invaded the submucosal layer and had been resected noncuratively because of a positive vertical margin (n = 2) or positive lymphovascular invasion (n = 5). No immediate or delayed complications, including major bleeding or perforation, and no ESD-related deaths occurred. At a mean follow-up period of 26.5 (range, 5–55) months, local recurrence had developed at the treatment site in 2 patient. Overall, 10 patients were still alive. The remaining 4 had developed lymph node metastasis, 2 of whom had died from it. Conclusions: Salvage ESD is an option for ESCC patients with local treatment failure after CT, RT, or CRT.

  • Endocytoscopy is a promising modality with high diagnostic accuracy for gastric cancer

    by Mitsuru Kaise, Yasuo Ohkura, Toshiro Iizuka, Ryusuke Kimura, Kosuke Nomura, Yasutaka Kuribayashi, Akihiro Yamada, Satoshi Yamashita, Tsukasa Furuhata, Daisuke Kikuchi, et al.

    Background and study aim: Endocytoscopy (ECS) enables in vivo microscopic imaging, which allows analysis of mucosal structures at the cellular level; however, limited data are available on the validity of ECS in the stomach. The aim of this study was to evaluate the feasibility of ECS in the diagnosis of early gastric cancer. Patients and methods: Gastric lesions that were the targets of histopathological diagnosis by endoscopic submucosal dissection or biopsy specimen were prospectively enrolled and evaluated using a single charge-coupled device-integrated endocytoscope, following double staining with crystal violet and methylene blue. High grade ECS atypia was defined according to specific irregularities in gland structure and cell nuclei. The primary end point was the accuracy of ECS diagnosis for gastric cancer, using histopathological diagnosis as the gold standard. Results: A total of 82 lesions were investigated, including 23 early gastric cancers, 10 gastric adenomas, and 49 non-neoplastic lesions. Ten lesions could not be clearly observed by ECS because of poor staining due to viscous mucus or plaque; thus, assessability rates with ECS were 88 % in total and 91 % for gastric cancer. High grade ECS atypia was observed in 86 % of assessable gastric cancers, but not in any cases of gastric adenomas or non-neoplastic lesions. The sensitivity, specificity, positive and negative predictive values of high grade ECS atypia as the criterion for the diagnosis of gastric cancer were 86 %, 100 %, 100 %, and 94 %, respectively. No serious complications occurred during or after the examinations. Conclusion: ECS is a clinically feasible modality to obtain in vivo histology, with high diagnostic accuracy in gastric cancer.


  • A new device for simultaneous manipulation of an endoscope and a treatment device during procedures: an ex vivo animal study

    by Daisuke Kikuchi, Akihiro Yamada, Toshiro Iizuka, Kosuke Nomura, Yasutaka Kuribayashi, Ryusuke Kimura, Satoshi Yamashita, Tsukasa Furuhata, Akira Matsui, Toshifumi Mitani, et al.

    Background and study aims: Endoscopists must maneuver both endoscope and treatment device during procedures, requiring them to release their hand from the scope to manipulate the treatment device. Aiming to improve this situation, we developed a new device called the Thumb Drive. Patients and methods: The Thumb Drive comprises a controller and catheter. After attaching the controller to the endoscope’s grip, the catheter is inserted into the forceps channel. The treatment device is then inserted into the Thumb Drive and fixed with its tip protruding from the endoscope tip. A single endoscopist resected 10 lesions in a porcine stomach by endoscopic submucosal dissection (ESD) using the Thumb Drive. Results: All lesions were resected en bloc using this new device without any perforations. The mean incision, dissection, and operative times were 97.2 ± 48.7 seconds, 121.6 ± 53.6 seconds, and 218.8 ± 67.8 seconds, respectively. Conclusions: The Thumb Drive enables the endoscopist to manipulate the treatment device with the thumb while handling the endoscope with the right hand during ESD. Its utility should be examined in in vivo studies as a next step.